{
  "company": {
    "name": "Invasight",
    "website": "https://invasight.com/",
    "record": "https://startuphistory.org/c/invasight.com"
  },
  "status": null,
  "history_since": "2021-06-23T03:17:55.000Z",
  "baseline": {
    "snapshot_id": "8dcf2c7094207d3f205df47fbc0fcc13f13ea53bdc13c7681833b00f4f7cea63",
    "observed_at": "2021-06-23T03:17:55.000Z",
    "headline": "Invasight- Home",
    "description": "First-in-class, protein-protein interaction inhibitors against invasive cancers.",
    "evidence": "https://web.archive.org/web/20210623031755/https://invasight.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [
    {
      "quote_observed_at": "2022-07-11T03:52:22.000Z",
      "variants": [
        {
          "headline": "Invasight- Home",
          "subhead": "First-in-class, protein-protein interaction inhibitors against invasive cancers.",
          "observed_at": "2021-06-23T03:17:55.000Z",
          "evidence": "https://web.archive.org/web/20210623031755/https://invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Invasight- Home",
          "subhead": "First-in-class, protein-protein interaction inhibitors against invasive cancers.",
          "observed_at": "2022-06-09T05:15:34.000Z",
          "evidence": "https://web.archive.org/web/20220609051534/https://invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Invasight- Home",
          "subhead": "First-in-class, protein-protein interaction inhibitors against invasive cancers.",
          "observed_at": "2022-07-11T03:52:22.000Z",
          "evidence": "https://web.archive.org/web/20220711035222/https://invasight.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Invasight- Home",
      "subhead": "First-in-class, protein-protein interaction inhibitors against invasive cancers.",
      "from": "2021-06-23T03:17:55.000Z",
      "to": "2022-07-11T03:52:22.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20220711035222/https://invasight.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-06-23T03:17:55.000Z",
          "to": "2022-07-11T03:52:22.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2025-07-24T03:08:15.000Z",
      "variants": [
        {
          "headline": "Advanced targeted therapies for invasive cancers",
          "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
          "observed_at": "2023-01-19T08:26:34.000Z",
          "evidence": "https://web.archive.org/web/20230119082634/https://www.invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advanced targeted therapies for invasive cancers",
          "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
          "observed_at": "2023-09-26T20:04:33.000Z",
          "evidence": "https://web.archive.org/web/20230926200433/https://www.invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advanced targeted therapies for invasive cancers",
          "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
          "observed_at": "2024-01-04T02:39:59.000Z",
          "evidence": "https://web.archive.org/web/20240104023959/https://www.invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advanced targeted therapies for invasive cancers",
          "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
          "observed_at": "2024-08-05T07:51:33.000Z",
          "evidence": "https://web.archive.org/web/20240805075133/https://www.invasight.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Advanced targeted therapies for invasive cancers",
          "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
          "observed_at": "2025-07-24T03:08:15.000Z",
          "evidence": "https://web.archive.org/web/20250724030815/https://www.invasight.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Advanced targeted therapies for invasive cancers",
      "subhead": "This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduc",
      "from": "2023-01-19T08:26:34.000Z",
      "to": "2025-07-24T03:08:15.000Z",
      "captures": 5,
      "evidence": "https://web.archive.org/web/20250724030815/https://www.invasight.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2023-01-19T08:26:34.000Z",
          "to": "2025-07-24T03:08:15.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Invasight” company record, https://startuphistory.org/c/invasight.com"
}